Event Brief
Daraxonrasib pill shows promise in early pancreatic cancer trial
Filed: May 18, 2026 at 8:02 AM ET
Summary: Daraxonrasib, a daily pill targeting RAS-linked signals, completed a first-in-human trial in 168 patients with advanced pancreatic cancer.
WHO: Dana-Farber Cancer Institute
WHAT: First-in-human trial of daraxonrasib in 168 patients with advanced pancreatic cancer and RAS mutations evaluated safety and effectiveness.
WHEN: May 18, 2026 at 7:00 AM ET
WHERE: Location not specified
WHY: The drug was tested to evaluate its safety and effectiveness in people with advanced pancreatic cancer with RAS mutations.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
🔍 9 sources analyzed
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →